30 http://www.imeronline.com en-us Institute for Medical Education and Research Institute for Medical Education and Research Institute for Medical Education and Research podcast@imeronline.com Online CE Programs podcast@imeronline.com http://www.imeronline.com/podcast/itunes300x300.jpg clean IMER Medical Education Oncology Nursing Cancer Pain Entire Audio Program Institute for Medical Education and Research 02:17:35 http://www.imeronline.com/podcast/media/125_entire.mp3 Mon, 02 Jul 2007 16:06:16 -0400 Mon, 02 Jul 2007 16:06:16 -0400 The past decade has witnessed major advances in the treatment of breast cancer as targeted therapies have been incorporated into standard chemotherapy regimens. In this educational symposium, the rationale for targeting specific molecular pathways in breast cancer treatment will be reviewed, and results of recent clinical trials evaluating targeted agents in the treatment metastatic and primary breast cancer will be presented. Appropriate nursing management of patients receiving these therapies will also be discussed. IMER, breast cancer, treatment, oncology Entire Audio Program Institute for Medical Education and Research 02:02:39 http://www.imeronline.com/podcast/media/122_oh_bc_entire.mp3 Mon, 02 Jul 2007 16:10:48 -0400 Mon, 02 Jul 2007 16:10:48 -0400 A recent key advancement in the treatment of breast cancer has been the use of therapies directed against specific molecular targets involved in the processes of tumor cell growth, proliferation, and invasion. Recent clinical trial data have emerged on targeted therapies in the first-line treatment of metastatic breast cancer and the adjuvant treatment of HER2-positive primary breast cancer. These data will be reviewed and discussed in this case-based symposium. IMER, breast cancer, treatment, oncology Introduction Institute for Medical Education and Research 00:00:28 http://www.imeronline.com/podcast/media/207_intro.mp4 Thu, 19 Jul 2007 11:22:38 -0400 Thu, 19 Jul 2007 11:22:38 -0400 Recently, exciting clinical data on targeted therapies in breast cancer have been presented, and changes in clinical practice are beginning to occur. This live panel discussion will feature real cases of breast cancer patients from the practices of key opinion leader oncology physician and nurse panelists. A well known oncology nurse breast specialist will moderate the event, leading each case discussion from initial diagnosis to actual clinical course, including treatment choices, side effects experienced and their management, and patients’ concerns. Questions posed to the audience and panelists will facilitate discussions and reinforce learning objectives. IMER, breast cancer, treatment, oncology, targeted therapies Episode 1 Institute for Medical Education and Research 00:23:12 http://www.imeronline.com/podcast/media/207_podcast_ep_1.mp4 Thu, 19 Jul 2007 11:23:59 -0400 Thu, 19 Jul 2007 11:23:59 -0400 Recently, exciting clinical data on targeted therapies in breast cancer have been presented, and changes in clinical practice are beginning to occur. This live panel discussion will feature real cases of breast cancer patients from the practices of key opinion leader oncology physician and nurse panelists. A well known oncology nurse breast specialist will moderate the event, leading each case discussion from initial diagnosis to actual clinical course, including treatment choices, side effects experienced and their management, and patients’ concerns. Questions posed to the audience and panelists will facilitate discussions and reinforce learning objectives. IMER, breast cancer, treatment, oncology, targeted therapies Episode 2 Institute for Medical Education and Research 00:26:09 http://www.imeronline.com/podcast/media/207_podcast_ep_2.mp4 Thu, 19 Jul 2007 11:25:09 -0400 Thu, 19 Jul 2007 11:25:09 -0400 Recently, exciting clinical data on targeted therapies in breast cancer have been presented, and changes in clinical practice are beginning to occur. This live panel discussion will feature real cases of breast cancer patients from the practices of key opinion leader oncology physician and nurse panelists. A well known oncology nurse breast specialist will moderate the event, leading each case discussion from initial diagnosis to actual clinical course, including treatment choices, side effects experienced and their management, and patients’ concerns. Questions posed to the audience and panelists will facilitate discussions and reinforce learning objectives. IMER, breast cancer, treatment, oncology, targeted therapies Episode 3 Institute for Medical Education and Research 00:21:05 http://www.imeronline.com/podcast/media/207_podcast_ep_3.mp4 Thu, 19 Jul 2007 11:31:24 -0400 Thu, 19 Jul 2007 11:31:24 -0400 Recently, exciting clinical data on targeted therapies in breast cancer have been presented, and changes in clinical practice are beginning to occur. This live panel discussion will feature real cases of breast cancer patients from the practices of key opinion leader oncology physician and nurse panelists. A well known oncology nurse breast specialist will moderate the event, leading each case discussion from initial diagnosis to actual clinical course, including treatment choices, side effects experienced and their management, and patients’ concerns. Questions posed to the audience and panelists will facilitate discussions and reinforce learning objectives. IMER, breast cancer, treatment, oncology, targeted therapies Episode 4 Institute for Medical Education and Research 00:23:31 http://www.imeronline.com/podcast/media/207_podcast_ep_4.mp4 Thu, 19 Jul 2007 11:32:27 -0400 Thu, 19 Jul 2007 11:32:27 -0400 Recently, exciting clinical data on targeted therapies in breast cancer have been presented, and changes in clinical practice are beginning to occur. This live panel discussion will feature real cases of breast cancer patients from the practices of key opinion leader oncology physician and nurse panelists. A well known oncology nurse breast specialist will moderate the event, leading each case discussion from initial diagnosis to actual clinical course, including treatment choices, side effects experienced and their management, and patients’ concerns. Questions posed to the audience and panelists will facilitate discussions and reinforce learning objectives. IMER, breast cancer, treatment, oncology, targeted therapies Episode 5 Institute for Medical Education and Research 00:25:40 http://www.imeronline.com/podcast/media/207_podcast_ep_5.mp4 Thu, 19 Jul 2007 11:33:38 -0400 Thu, 19 Jul 2007 11:33:38 -0400 Recently, exciting clinical data on targeted therapies in breast cancer have been presented, and changes in clinical practice are beginning to occur. This live panel discussion will feature real cases of breast cancer patients from the practices of key opinion leader oncology physician and nurse panelists. A well known oncology nurse breast specialist will moderate the event, leading each case discussion from initial diagnosis to actual clinical course, including treatment choices, side effects experienced and their management, and patients’ concerns. Questions posed to the audience and panelists will facilitate discussions and reinforce learning objectives. IMER, breast cancer, treatment, oncology, targeted therapies End Institute for Medical Education and Research 00:02:12 http://www.imeronline.com/podcast/media/207_end.mp4 Thu, 19 Jul 2007 11:35:07 -0400 Thu, 19 Jul 2007 11:35:07 -0400 Recently, exciting clinical data on targeted therapies in breast cancer have been presented, and changes in clinical practice are beginning to occur. This live panel discussion will feature real cases of breast cancer patients from the practices of key opinion leader oncology physician and nurse panelists. A well known oncology nurse breast specialist will moderate the event, leading each case discussion from initial diagnosis to actual clinical course, including treatment choices, side effects experienced and their management, and patients’ concerns. Questions posed to the audience and panelists will facilitate discussions and reinforce learning objectives. IMER, breast cancer, treatment, oncology, targeted therapies Episode 2 Institute for Medical Education and Research 00:21:08 http://www.imeronline.com/podcast/media/250_smith1.mp4 Fri, 12 Oct 2007 16:10:51 -0400 Fri, 12 Oct 2007 16:10:51 -0400 In recent years, paradigm shifts in the multimodal treatment of breast cancer have occurred based on the successful incorporation of targeted therapies. Since 2004, several educational initiatives on this topic have been held, and excellent oncology nurse questions worthy of detailed responses have been submitted, addressing such issues as targeted therapy mechanisms of action, current and expected future targeted therapy clinical applications, and nursing management strategies. During this interactive, 2-hour educational program, expert panelists will present these frequently asked questions. Attendees’ understanding of presented issues and their own practice patterns will be questioned via audience response technology. Finally, the program will conclude with a tribute to singer-songwriter Soraya, who lost her battle with breast cancer in 2006. Soraya was a national spokesperson for breast cancer causes and urged women everywhere to empower themselves and make educated treatment choices. IMER, breast cancer, treatment, oncology, epothilones Episode 3 Institute for Medical Education and Research 00:33:33 http://www.imeronline.com/podcast/media/250_rugo1.mp4 Fri, 12 Oct 2007 16:12:48 -0400 Fri, 12 Oct 2007 16:12:48 -0400 In recent years, paradigm shifts in the multimodal treatment of breast cancer have occurred based on the successful incorporation of targeted therapies. Since 2004, several educational initiatives on this topic have been held, and excellent oncology nurse questions worthy of detailed responses have been submitted, addressing such issues as targeted therapy mechanisms of action, current and expected future targeted therapy clinical applications, and nursing management strategies. During this interactive, 2-hour educational program, expert panelists will present these frequently asked questions. Attendees’ understanding of presented issues and their own practice patterns will be questioned via audience response technology. Finally, the program will conclude with a tribute to singer-songwriter Soraya, who lost her battle with breast cancer in 2006. Soraya was a national spokesperson for breast cancer causes and urged women everywhere to empower themselves and make educated treatment choices. IMER, breast cancer, treatment, oncology, targeted therapies Episode 4 Institute for Medical Education and Research 00:27:08 http://www.imeronline.com/podcast/media/250_rymer.mp4 Fri, 12 Oct 2007 16:35:25 -0400 Fri, 12 Oct 2007 16:35:25 -0400 In recent years, paradigm shifts in the multimodal treatment of breast cancer have occurred based on the successful incorporation of targeted therapies. Since 2004, several educational initiatives on this topic have been held, and excellent oncology nurse questions worthy of detailed responses have been submitted, addressing such issues as targeted therapy mechanisms of action, current and expected future targeted therapy clinical applications, and nursing management strategies. During this interactive, 2-hour educational program, expert panelists will present these frequently asked questions. Attendees’ understanding of presented issues and their own practice patterns will be questioned via audience response technology. Finally, the program will conclude with a tribute to singer-songwriter Soraya, who lost her battle with breast cancer in 2006. Soraya was a national spokesperson for breast cancer causes and urged women everywhere to empower themselves and make educated treatment choices. IMER, breast cancer, treatment, oncology, targeted therapies Episode 5 Institute for Medical Education and Research 00:23:03 http://www.imeronline.com/podcast/media/250_qanda.mp4 Fri, 12 Oct 2007 16:45:19 -0400 Fri, 12 Oct 2007 16:45:19 -0400 In recent years, paradigm shifts in the multimodal treatment of breast cancer have occurred based on the successful incorporation of targeted therapies. Since 2004, several educational initiatives on this topic have been held, and excellent oncology nurse questions worthy of detailed responses have been submitted, addressing such issues as targeted therapy mechanisms of action, current and expected future targeted therapy clinical applications, and nursing management strategies. During this interactive, 2-hour educational program, expert panelists will present these frequently asked questions. Attendees’ understanding of presented issues and their own practice patterns will be questioned via audience response technology. Finally, the program will conclude with a tribute to singer-songwriter Soraya, who lost her battle with breast cancer in 2006. Soraya was a national spokesperson for breast cancer causes and urged women everywhere to empower themselves and make educated treatment choices. IMER, breast cancer, treatment, oncology, targeted therapies Episode 1 Institute for Medical Education and Research 00:06:37 http://www.imeronline.com/podcast/media/250_major1.mp4 Tue, 16 Oct 2007 15:20:25 -0400 Tue, 16 Oct 2007 15:20:25 -0400 In recent years, paradigm shifts in the multimodal treatment of breast cancer have occurred based on the successful incorporation of targeted therapies. Since 2004, several educational initiatives on this topic have been held, and excellent oncology nurse questions worthy of detailed responses have been submitted, addressing such issues as targeted therapy mechanisms of action, current and expected future targeted therapy clinical applications, and nursing management strategies. During this interactive, 2-hour educational program, expert panelists will present these frequently asked questions. Attendees’ understanding of presented issues and their own practice patterns will be questioned via audience response technology. Finally, the program will conclude with a tribute to singer-songwriter Soraya, who lost her battle with breast cancer in 2006. Soraya was a national spokesperson for breast cancer causes and urged women everywhere to empower themselves and make educated treatment choices. IMER, monoclonal antibody, therapy, nhl, non-hodgkin's lymphoma, treatment, prognosis Episode 1 Institute for Medical Education and Research 00:35:50 http://www.imeronline.com/podcast/media/225_ep_1.mp4 Mon, 22 Oct 2007 14:42:07 -0400 Mon, 22 Oct 2007 14:42:07 -0400 With advances in the understanding of cellular and molecular signaling transduction in breast cancer, novel biologic therapies that target a variety of signaling pathways have emerged within the last decade. More recently, therapies acting on targets involved in tumor angiogenesis and proliferation in breast cancer have demonstrated positive results, which will lead to changing paradigms in breast cancer treatment. Also, based on positive outcomes of recent clinical trials, targeted therapies are now being employed in the adjuvant setting. All of these topics will be discussed, as well as their evolving role in the treatment of breast cancer. It is critical that oncology nurses understand recent emerging data on these novel therapies to better support breast cancer patients. This educational symposium will review the most recent innovations in targeted therapies for breast cancer. A case-based interactive discussion will highlight the nurse’s role in optimal management of these patients. IMER, breast cancer, treatment, oncology, targeted therapies, molecular signaling transduction Episode 2 Institute for Medical Education and Research 00:58:34 http://www.imeronline.com/podcast/media/225_ep_2.mp4 Mon, 22 Oct 2007 14:43:54 -0400 Mon, 22 Oct 2007 14:43:54 -0400 With advances in the understanding of cellular and molecular signaling transduction in breast cancer, novel biologic therapies that target a variety of signaling pathways have emerged within the last decade. More recently, therapies acting on targets involved in tumor angiogenesis and proliferation in breast cancer have demonstrated positive results, which will lead to changing paradigms in breast cancer treatment. Also, based on positive outcomes of recent clinical trials, targeted therapies are now being employed in the adjuvant setting. All of these topics will be discussed, as well as their evolving role in the treatment of breast cancer. It is critical that oncology nurses understand recent emerging data on these novel therapies to better support breast cancer patients. This educational symposium will review the most recent innovations in targeted therapies for breast cancer. A case-based interactive discussion will highlight the nurse’s role in optimal management of these patients. IMER, breast cancer, treatment, oncology, targeted therapies, molecular signaling transduction Episode 3 Institute for Medical Education and Research 00:35:10 http://www.imeronline.com/podcast/media/225_ep_3.mp4 Mon, 22 Oct 2007 14:49:05 -0400 Mon, 22 Oct 2007 14:49:05 -0400 With advances in the understanding of cellular and molecular signaling transduction in breast cancer, novel biologic therapies that target a variety of signaling pathways have emerged within the last decade. More recently, therapies acting on targets involved in tumor angiogenesis and proliferation in breast cancer have demonstrated positive results, which will lead to changing paradigms in breast cancer treatment. Also, based on positive outcomes of recent clinical trials, targeted therapies are now being employed in the adjuvant setting. All of these topics will be discussed, as well as their evolving role in the treatment of breast cancer. It is critical that oncology nurses understand recent emerging data on these novel therapies to better support breast cancer patients. This educational symposium will review the most recent innovations in targeted therapies for breast cancer. A case-based interactive discussion will highlight the nurse’s role in optimal management of these patients. IMER, breast cancer, treatment, oncology, targeted therapies, molecular signaling transduction Episode 4 Institute for Medical Education and Research 00:12:20 http://www.imeronline.com/podcast/media/225_ep_4.mp4 Mon, 22 Oct 2007 14:49:50 -0400 Mon, 22 Oct 2007 14:49:50 -0400 With advances in the understanding of cellular and molecular signaling transduction in breast cancer, novel biologic therapies that target a variety of signaling pathways have emerged within the last decade. More recently, therapies acting on targets involved in tumor angiogenesis and proliferation in breast cancer have demonstrated positive results, which will lead to changing paradigms in breast cancer treatment. Also, based on positive outcomes of recent clinical trials, targeted therapies are now being employed in the adjuvant setting. All of these topics will be discussed, as well as their evolving role in the treatment of breast cancer. It is critical that oncology nurses understand recent emerging data on these novel therapies to better support breast cancer patients. This educational symposium will review the most recent innovations in targeted therapies for breast cancer. A case-based interactive discussion will highlight the nurse’s role in optimal management of these patients. IMER, breast cancer, treatment, oncology, targeted therapies, molecular signaling transduction Introduction Institute for Medical Education and Research 00:05:34 http://www.imeronline.com/podcast/media/236_intro.m4v Fri, 12 Oct 2007 15:02:51 -0400 Fri, 12 Oct 2007 15:02:51 -0400 More than 220,000 cases of newly diagnosed breast cancer are expected this year in the United States. Approximately 25% will have recurrent or metastatic disease, treatment for which typically includes systemic chemotherapy with or without a biologic agent. Targeting of the microtubule has been shown to be an effective means of producing anticancer effects, as evidenced by the widespread incorporation of vinca alkaloids and taxanes into treatment regimens. However, these treatments are often associated with a narrow margin between benefit and toxicity, and resistance develops over continued use. Epothilone chemotherapies, with broadspectrum antitumor effects, have been under investigation in metastatic breast cancer in recent years. Epothilones have demonstrated antitumor activity in taxane-resistant cancer cells and they are now under investigation as single agents and in combination with biologic agents in patients who have failed taxane therapy. This program is intended to educate oncology nurses about epothilones so they may better educate patients and prevent and/or manage unique side effects that may be experienced. A 3-D video will be used to illustrate the mechanism of action of epothilones and other chemotherapies targeting the microtubule. IMER, breast cancer, treatment, oncology, epothilones Episode 2 Institute for Medical Education and Research 00:22:31 http://www.imeronline.com/podcast/media/236_cusack.m4v Fri, 12 Oct 2007 15:10:22 -0400 Fri, 12 Oct 2007 15:12:37 -0400 More than 220,000 cases of newly diagnosed breast cancer are expected this year in the United States. Approximately 25% will have recurrent or metastatic disease, treatment for which typically includes systemic chemotherapy with or without a biologic agent. Targeting of the microtubule has been shown to be an effective means of producing anticancer effects, as evidenced by the widespread incorporation of vinca alkaloids and taxanes into treatment regimens. However, these treatments are often associated with a narrow margin between benefit and toxicity, and resistance develops over continued use. Epothilone chemotherapies, with broadspectrum antitumor effects, have been under investigation in metastatic breast cancer in recent years. Epothilones have demonstrated antitumor activity in taxane-resistant cancer cells and they are now under investigation as single agents and in combination with biologic agents in patients who have failed taxane therapy. This program is intended to educate oncology nurses about epothilones so they may better educate patients and prevent and/or manage unique side effects that may be experienced. A 3-D video will be used to illustrate the mechanism of action of epothilones and other chemotherapies targeting the microtubule. IMER, breast cancer, treatment, oncology, epothilones Episode 3 Institute for Medical Education and Research 00:21:23 http://www.imeronline.com/podcast/media/236_vahdat.m4v Fri, 12 Oct 2007 15:11:58 -0400 Fri, 12 Oct 2007 15:11:58 -0400 More than 220,000 cases of newly diagnosed breast cancer are expected this year in the United States. Approximately 25% will have recurrent or metastatic disease, treatment for which typically includes systemic chemotherapy with or without a biologic agent. Targeting of the microtubule has been shown to be an effective means of producing anticancer effects, as evidenced by the widespread incorporation of vinca alkaloids and taxanes into treatment regimens. However, these treatments are often associated with a narrow margin between benefit and toxicity, and resistance develops over continued use. Epothilone chemotherapies, with broadspectrum antitumor effects, have been under investigation in metastatic breast cancer in recent years. Epothilones have demonstrated antitumor activity in taxane-resistant cancer cells and they are now under investigation as single agents and in combination with biologic agents in patients who have failed taxane therapy. This program is intended to educate oncology nurses about epothilones so they may better educate patients and prevent and/or manage unique side effects that may be experienced. A 3-D video will be used to illustrate the mechanism of action of epothilones and other chemotherapies targeting the microtubule. IMER, breast cancer, treatment, oncology, epothilones Episode 4 Institute for Medical Education and Research 00:26:48 http://www.imeronline.com/podcast/media/236_palmieri.m4v Fri, 12 Oct 2007 15:17:03 -0400 Fri, 12 Oct 2007 15:17:03 -0400 More than 220,000 cases of newly diagnosed breast cancer are expected this year in the United States. Approximately 25% will have recurrent or metastatic disease, treatment for which typically includes systemic chemotherapy with or without a biologic agent. Targeting of the microtubule has been shown to be an effective means of producing anticancer effects, as evidenced by the widespread incorporation of vinca alkaloids and taxanes into treatment regimens. However, these treatments are often associated with a narrow margin between benefit and toxicity, and resistance develops over continued use. Epothilone chemotherapies, with broadspectrum antitumor effects, have been under investigation in metastatic breast cancer in recent years. Epothilones have demonstrated antitumor activity in taxane-resistant cancer cells and they are now under investigation as single agents and in combination with biologic agents in patients who have failed taxane therapy. This program is intended to educate oncology nurses about epothilones so they may better educate patients and prevent and/or manage unique side effects that may be experienced. A 3-D video will be used to illustrate the mechanism of action of epothilones and other chemotherapies targeting the microtubule. IMER, breast cancer, treatment, oncology, epothilones Episode 5 Institute for Medical Education and Research 00:09:07 http://www.imeronline.com/podcast/media/236_qa.m4v Fri, 12 Oct 2007 15:21:35 -0400 Fri, 12 Oct 2007 15:21:35 -0400 More than 220,000 cases of newly diagnosed breast cancer are expected this year in the United States. Approximately 25% will have recurrent or metastatic disease, treatment for which typically includes systemic chemotherapy with or without a biologic agent. Targeting of the microtubule has been shown to be an effective means of producing anticancer effects, as evidenced by the widespread incorporation of vinca alkaloids and taxanes into treatment regimens. However, these treatments are often associated with a narrow margin between benefit and toxicity, and resistance develops over continued use. Epothilone chemotherapies, with broadspectrum antitumor effects, have been under investigation in metastatic breast cancer in recent years. Epothilones have demonstrated antitumor activity in taxane-resistant cancer cells and they are now under investigation as single agents and in combination with biologic agents in patients who have failed taxane therapy. This program is intended to educate oncology nurses about epothilones so they may better educate patients and prevent and/or manage unique side effects that may be experienced. A 3-D video will be used to illustrate the mechanism of action of epothilones and other chemotherapies targeting the microtubule. IMER, breast cancer, treatment, oncology, epothilones